FGFR

下级目录

AZD4547
Lucitanib
Derazantinib
LY2874455
FIIN-1
Debio-1347
BLU9931
FIIN-2
FIIN-3
ACTB-1003
1-(2,4-Difluorophenyl)-3-(4-(6,7-dimethoxyquinolin-4-yloxy)-2-fluorophenyl)urea

目录项下的产品

1035270-39-3
1058137-23-7
1234356-69-4
1254473-64-7
1256152-35-8
1265229-25-1
1538604-68-0
1633044-56-0
1637735-84-2
939805-30-8
939805-30-8 / MFCD039805308
ACTB-1003 is an oral kinase inhibitor targeting cancer mutations (FGFR inhibition), angiogenesis (inhibition of VEGFR2 and Tie-2) and induces apoptosis (targeting RSK and p70S6K, downstream of PI3 kinase). The multi-activity of ACTB- 1003 translates to in vivo efficacy with dose-dependent tumor growth inhibition in a variety of histological cancers including lung, breast and colorectal. ACTB-1003 is an oral kinase inhibitor with multiple modes of action, targeting cancer mutations via FGFR inhibition FGFR1 (IC50=6 nM), angiogenesis through inhibition of VEGFR2 (2 nM), Tie-2 (4 nM), and induces apoptosis likely by targeting RSK (5 nM) and p70S6K (32 nM). ACTB-1003 is highly active with dose-dependent tumor growth inhibition in cell lines with FGFR genetic alterations - OPM2 human multiple myeloma and the murine leukemia Ba/F3-TEL-FGFR1.
228559-41-9